AstraZeneca has announced a partnership with Honeywell for development of lower global warming potential MDIs using HFO-1234ze as a propellant. The company said that Breztri budesonide/ glycopyrronium/ formoterol fumarate is the first product it plans to convert to HFO-1234ze and that a Phase 1 trial of an HFO 1234ze formulation of budesonide/ glycopyrronium/ formoterol fumarate demonstrated PK, safety, and tolerability results similar to Breztri Aerosphere.
In November 2021, Kindeva Drug Delivery announced that it was installing a new MDI line capable of filling either HFO-1234ze or HFA-152a and said that it expected to launch two lower-GWP products by 2025. Several projects using HFA-152a have been announced, including Chiesi’s planned launch of an HFA-152a MDI by the end of 2025.
AstraZeneca CEO Pascal Soriot commented, “We are making great progress on our ambition to be zero carbon across our global operations by the end of 2025 and carbon negative across our entire value chain by 2030. Our collaboration with Honeywell demonstrates AstraZeneca’s commitment to advancing sustainable healthcare innovation, with the aim of improving outcomes for patients while reducing our environmental footprint.”
Honeywell Chairman and CEO Darius Adamczyk said, “The work we are doing with AstraZeneca developing a respiratory inhaler, with a new near-zero global warming potential propellant, is tremendously important for both the environment and patients with respiratory issues. Our goal is to reduce respiratory healthcare carbon emissions without restricting patient choice or risking improvement in health outcomes.”
Read the AstraZeneca press release.
